Kenanga launches world first Hang Seng Biotech Index structured warrants

KUALA LUMPUR, Malaysia - Kenanga Investment Bank Berhad, also known as The Group, has introduced the world's first structured warrants tied to the Hang Seng Biotech Index (HSBIO) under its NagaWarrants product line. The new warrants, HSBIO-CAA (0661AA) and HSBIO-HBA (0661BA), offer Malaysian investors access to Hong Kong's biotechnology and healthcare sector, a thriving long-term growth theme fueled by demographic changes, increasing healthcare demand, and ongoing medical advancements.

This innovation positions HSBIO within the NagaWarrants range, which already includes products tied to the Hang Seng Index, Hang Seng China Enterprises Index, and Hang Seng TECH Index. The launch event occurred during the 11th Belt and Road Summit in Hong Kong, bringing together Kenanga Group and Hang Seng Indexes Company representatives.

HSBIO tracks 30 of the largest biotech and healthcare firms listed in Hong Kong, with a 64.5% gain in 2025, outpacing other indices. The index's expanding ecosystem, including futures contracts and ETFs worth over HKD11 billion in assets, highlights the growing appeal of biotechnology investments. By launching HSBIO-linked structured warrants, Kenanga demonstrates its dedication to product innovation, offering Malaysian investors a new avenue to participate in global market trends through a familiar structured warrant format.